Hims & Hers is sunsetting Apostrophe, a skin care startup that it bought in 2021 for $190 million, Business Insider first reported on Friday.
A message on Apostrophe’s website says all current subscriptions will be canceled as of March 7. The company told BI it did this to “simplify our dermatology products and operations into one seamless experience.” Hims & Hers’ flagship platform has dermatology offerings, though not everything that Apostrophe provided.
Hims & Hers shares were basically flat. The telepharmacy was also inducted into the S&P 400 midcap index on Monday, exposing it to more investors’ ownership.